Clinical and laboratory characteristics of the patients investigated at the molecular level
| . | Total patients fully characterized . | Total patients no or only partially characterized . | P . | EU patients fully characterized . | EU patients no or only partially characterized . | P . | IR patients fully characterized . | IR patients no or only partially characterized . | P . |
|---|---|---|---|---|---|---|---|---|---|
| N | 207 | 24 | 105 | 16 | 102 | 8 | |||
| Sex | |||||||||
| Male | 87 (42%) | 8 (33%) | 37 (35.2%) | 6 (37.5%) | 50 (49%) | 2 (25%) | |||
| Female | 120 (58%) | 16 (67%) | 68 (64.8%) | 10 (62.5%) | 52 (51%) | 6 (75%) | |||
| Age at study inclusion, y | 28 (16-43) | 38 (20-51) | .08 | 40 (25-49) | 42 (33-54) | .40 | 22 (8-30) | 21 (14-34) | .39 |
| Bleeding score | 15 (8-21) | 11 (7-18) | .30 | 18 (14-25) | 15 (11-19) | .07 | 10 (4-16) | 8 (5-10) | .42 |
| N* | 157 | 20 | 69 | 12 | 88 | 8 | |||
| VWF:Ag* | 0.5 (0.5-0.5) | 2.2 (0.8-3.9) | <.001 | 0.5 (0.5-1.3) | 3.9 (0.8-4.6) | .003 | 0.5 (0.5-0.5) | 1.8 (1.1-2.3) | <.001 |
| FVIII:C* | 2.4 (1.9-3.2) | 2.7 (1.8-8.4) | .29 | 2.7 (2.2-3.7) | 5.5 (2.5-16.9) | .07 | 2.2 (1.7-2.6) | 1.8 (1.6-2.3) | .42 |
| . | Total patients fully characterized . | Total patients no or only partially characterized . | P . | EU patients fully characterized . | EU patients no or only partially characterized . | P . | IR patients fully characterized . | IR patients no or only partially characterized . | P . |
|---|---|---|---|---|---|---|---|---|---|
| N | 207 | 24 | 105 | 16 | 102 | 8 | |||
| Sex | |||||||||
| Male | 87 (42%) | 8 (33%) | 37 (35.2%) | 6 (37.5%) | 50 (49%) | 2 (25%) | |||
| Female | 120 (58%) | 16 (67%) | 68 (64.8%) | 10 (62.5%) | 52 (51%) | 6 (75%) | |||
| Age at study inclusion, y | 28 (16-43) | 38 (20-51) | .08 | 40 (25-49) | 42 (33-54) | .40 | 22 (8-30) | 21 (14-34) | .39 |
| Bleeding score | 15 (8-21) | 11 (7-18) | .30 | 18 (14-25) | 15 (11-19) | .07 | 10 (4-16) | 8 (5-10) | .42 |
| N* | 157 | 20 | 69 | 12 | 88 | 8 | |||
| VWF:Ag* | 0.5 (0.5-0.5) | 2.2 (0.8-3.9) | <.001 | 0.5 (0.5-1.3) | 3.9 (0.8-4.6) | .003 | 0.5 (0.5-0.5) | 1.8 (1.1-2.3) | <.001 |
| FVIII:C* | 2.4 (1.9-3.2) | 2.7 (1.8-8.4) | .29 | 2.7 (2.2-3.7) | 5.5 (2.5-16.9) | .07 | 2.2 (1.7-2.6) | 1.8 (1.6-2.3) | .42 |
For quantitative variables, median and interquartile range are reported; descriptive variables are reported as numbers with percentages. Mann-Whitney U test was used to evaluate the group comparisons.
Includes only the patients without prophylaxis.